Supported by an educational grant from Astellas Pharma US, Inc.
Even with improvements in induction therapy, post-remission strategies, and in tolerability of treatment regimens for patients with acute myeloid leukemia (AML) over the last several decades, better overall survival and progression-free survival has remained an ongoing challenge. However, recently approved and emerging targeted agents for AML are expected to dramatically change the treatment landscape, especially with regard to high-risk and FLT3+ relapsed or refractory AML. Understanding the clinical evidence is necessary to define the strengths, limitations, and selection of each targeted drug, alone and in combination. Ultimately, delivering the right treatment to the right patient translates into a chance for deeper and more durable responses and the best possible outcome for each patient with AML.
Hematologist-oncologists, oncology nurses, and advanced practitioners in oncology
After completing the activity, the participant should be better able to:
Utilize mutational analysis as indicated to guide treatment choice in AML
Identify the benefits and limitations of approved and emerging agents, including FLT3-targeted therapies
Apply effective patient-physician communication with shared decision-making about treatment choices to address psychosocial and emotional needs of the patient
Conflict Of Interest Disclosure Policies
In accordance with the ACCME Standards for Commercial Support, HME requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. HME resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational activities.
Alexander E. Perl, MD (Chair) Associate Professor of Medicine Leukemia Program Division of Hematology/Oncology University of Pennsylvania Philadelphia, PA
Dr. Perl receives consulting fees from Argo Pharmaceuticals, Astellas Pharma US, Inc., Daiichi-Sankyo Company Limited, Novartis Pharmaceuticals Corporation, and Pfizer Inc. He is on the advisory committees of Actinium Pharmaceuticals, Inc., and Asana Biosciences, LLC.
Naval G. Daver, MD Associate Professor Department of Leukemia Division of Cancer Medicine The University of Texas MD Anderson Cancer Center Houston, TX
Dr. Daver receives consulting fees from AbbVie Inc., Bristol-Myers Squibb Company, Daiichi-Sankyo Company Limited, Jazz Pharmaceuticals, Novartis Pharmaceuticals Corporation, Otsuka America Pharmaceutical, Inc., and Pfizer Inc. He also receives contracted research funds from AbbVie Inc., Bristol-Myers Squibb Company, Daiichi-Sankyo Company Limited, Genentech, Inc., GlycoMimetics, Inc., Incyte Corporation, Karyopharm Therapeutics, Pfizer Inc., Servier, and Sunesis Pharmaceuticals, Inc.
Amir T. Fathi, MD Assistant Professor of Medicine Massachusetts General Hospital Harvard School of Medicine Boston, MA
Dr. Fathi receives consulting fees from Astellas Pharma US, Inc., Boston Biomedical, Celgene Corporation, Jazz Pharmaceuticals, and Takeda Pharmaceutical Company Ltd. He also receives contracted research funds from Agios Inc., Celgene Corporation, Seattle Genetics, Inc., and Takeda Pharmaceutical Company Ltd.
Accredited Provider Disclosure
Haymarket Medical Education staff involved in the planning and content review of this activity have no relevant financial relationships to disclose.
AMA PRA Category 1 Credit(s)TM
Haymarket Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Haymarket Medical Education designates this enduring material for a maximum of 1.00 AMA PRA Category 1 CreditTM . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Additional Credit Information
Physician Assistant Continuing Education AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 CreditTM from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of 1.00 Category 1 Credits for completing this activity.
Nurse Practitioner Continuing Education The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts certificates of participation for educational activities certified for AMA PRA Category 1 CreditTM from organizations accredited by ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.
Disclosure of Unlabeled Use
This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient's medical condition.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Haymarket Medical Education or Astellas Pharma US, Inc. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.